Receive our newsletter – data, insights and analysis delivered to you
  1. News
January 5, 2017

Asana BioSciences begins Phase I trial of ASN003 to treat cancer

US-based clinical stage biopharmaceutical company Asana BioSciences has begun its Phase I trial of ASN003 to treat patients with advanced solid tumours.

US-based clinical stage biopharmaceutical company Asana BioSciences has begun its Phase I trial of ASN003 to treat patients with advanced solid tumours.

ASN003 selectively inhibits B-RAF and phosphoinositide 3-kinase (PI3K), while demonstrating wider anti-proliferative activity against tumour cell lines.

Activation of the two signalling pathways triggers abnormal cell growth in a range of cancers such as melanoma, colorectal, breast and lung.

ASN003 can treat or prevent resistance to selective B-Raf inhibitors.

The Phase I trial is being conducted as a multicentre, dose-finding, cohort expansion study, which will include patients with advanced solid tumours with B-RAF V600 mutation or PI3K pathway alterations, including those with metastatic colorectal cancer (CRC) or advanced non-small-cell lung cancer (NSCLC).

"ASN003 is our third clinical stage programme in less than two years, affirming Asana’s efficiency and dedication to provide new and better treatment options to cancer patients."

The study is intended to establish the safety, tolerability and determine pharmacokinetics, pharmacodynamics profile and anti-tumour activity of ASN003.

Content from our partners
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide
Why Asia-Pacific is the next frontier for decentralized clinical trials

Asana BioSciences founder, president and CEO Sandeep Gupta said: “We are delighted to initiate the clinical development of ASN003, which is a first-in-class, highly selective B-RAF / PI3K inhibitor designed to delay or treat acquired resistance observed in patients treated with current therapies targeting these individual pathways.

“The dosing of the first cohort in the trial has been completed, and the drug was well tolerated.

“ASN003 is our third clinical stage programme in less than two years, affirming Asana’s efficiency and dedication to provide new and better treatment options to cancer patients.”

ASN003 has also demonstrated anti-tumour activity when administered in combination with immune checkpoint and IDO inhibitors.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU